Geron's Q2'26 revenue update fails to dispel launch concerns as MF competition intensifies

What happened

Geron reported Q2'26 net product revenue of $57.5M, up 11% sequentially but still modest relative to the large LR-MDS addressable pool, and management declined to raise full-year guidance, only hinting at the mid-to-high end. The company faces growing competition in myelofibrosis as KPTI moves toward a frontline approval, while Geron's own Phase 3 IMpactMF targets the relapsed/refractory setting, which may be less attractive if frontline combinations gain traction. The revenue trend remains far below the 'blockbuster' trajectory management once implied, and the stock remains unloved after a 63% drawdown over the past year. The restructuring and cost-control efforts have yet to produce a clear inflection in demand, and the balance sheet still carries significant leverage and royalty obligations. Overall, this update does little to change the bearish-to-neutral bias, as commercial execution remains unproven and the MF catalyst is now clouded by competitor progress.

Implication

The Q2'26 revenue print and lack of guidance raise reinforce the need for patience. The WAIT rating from the master report remains appropriate: investors should only consider buying near the $1.10 attractive entry if subsequent quarters show sustained sequential growth and operational leverage, and should trim above $1.90 absent a major positive catalyst. The emerging MF competitive threat from KPTI in frontline settings could reduce the long-term opportunity for imetelstat in the relapsed/refractory niche, increasing the risk that the bull case ($2.20) becomes less likely. Monitor near-term catalysts: Q3'26 sales, any updates on EU launch progress, and the IMpactMF interim analysis timing. A break below $1.00 on continued revenue stagnation or negative MF news would signal a shift to the bear case ($0.70).

Thesis delta

The master report's WAIT thesis is reinforced by this update. Geron's Q2'26 revenue growth of 11% sequentially is insufficient to validate a turnaround, and the news does not address the critical issues of sales force execution or gross-to-net stability. The competitive threat from KPTI in frontline MF slightly reduces the probability of the bull case, as Geron's MF strategy is focused on a later-line niche that may shrink if frontline combinations become standard. No change to valuation anchors yet, but downside risk is increasing if sales do not accelerate in the next two quarters.